{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:02:59Z","timestamp":1791424979214,"version":"4.3.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"EDCPT2 programme","award":["RIA2017MC-2025-PYRAPREG"],"award-info":[{"award-number":["RIA2017MC-2025-PYRAPREG"]}]},{"name":"Global Health EDCTP3 Joint Undertaking","award":["101145638 PYRAPREG-extended"],"award-info":[{"award-number":["101145638 PYRAPREG-extended"]}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["VR 2022-01251"],"award-info":[{"award-number":["VR 2022-01251"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40262-025-01581-6","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T14:20:16Z","timestamp":1759242016000},"page":"1855-1867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Importance of Lysosomal Trapping and Plasmodium Parasite Infection on the Pharmacokinetics of Pyronaridine: A Physiologically Based Pharmacokinetic Model-Based Study"],"prefix":"10.1007","volume":"64","author":[{"given":"Wan-Yu","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wietse M.","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hypolite Muhindo","family":"Mavoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Japhet Kabalu","family":"Tshiongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doudou Malekita","family":"Yobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddy-Arnold","family":"Kabasele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustave","family":"Kasereka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivi","family":"Maketa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperan\u00e7a","family":"Sevene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anifa","family":"Vala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jangsik","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"D\u2019Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassoum","family":"Kayentao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P. C.","family":"Dorlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"1581_CR1","unstructured":"World Health Organization (WHO). World malaria report 2023 [Internet]. [cited 2025 May 11]. Available from: https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2023."},{"key":"1581_CR2","unstructured":"World Health Organization (WHO). WHO guidelines for malaria [Internet]. [cited 2025 May 11]. Available from: https:\/\/www.who.int\/publications\/i\/item\/guidelines-for-malaria."},{"key":"1581_CR3","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1093\/jac\/dkad260","volume":"78","author":"W-Y Chu","year":"2023","unstructured":"Chu W-Y, Dorlo TPC. Pyronaridine: a review of its clinical pharmacology in the treatment of malaria. J Antimicrob Chemother. 2023;78:2406\u201318.","journal-title":"J Antimicrob Chemother"},{"key":"1581_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-3075-5","volume":"19","author":"SA Charman","year":"2020","unstructured":"Charman SA, Andreu A, Barker H, Blundell S, Campbell A, Campbell M, et al. An in vitro toolbox to accelerate anti-malarial drug discovery and development. Malar J. 2020;19:1.","journal-title":"Malar J"},{"key":"1581_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1124\/dmd.118.084541","volume":"47","author":"MV Schmitt","year":"2019","unstructured":"Schmitt MV, Lienau P, Fricker G, Reichel A. Quantitation of lysosomal trapping of basic lipophilic compounds using in vitro assays and in silico predictions based on the determination of the full pH profile of the endo-\/lysosomal system in rat hepatocytes. Drug Metab Dispos. 2019;47:49\u201357.","journal-title":"Drug Metab Dispos"},{"key":"1581_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104908","volume":"182","author":"TR Lane","year":"2020","unstructured":"Lane TR, Dyall J, Mercer L, Goodin C, Foil DH, Zhou H, et al. Repurposing Pyramax\u00ae, quinacrine and tilorone as treatments for Ebola virus disease. Antivir Res. 2020;182:104908.","journal-title":"Antivir Res"},{"key":"1581_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1124\/jpet.103.056770","volume":"308","author":"GA Siebert","year":"2004","unstructured":"Siebert GA, Hung DY, Chang P, Roberts MS. Ion-trapping, microsomal binding, and unbound drug distribution in the hepatic retention of basic drugs. J Pharmacol Exp Ther. 2004;308:228\u201335.","journal-title":"J Pharmacol Exp Ther"},{"key":"1581_CR8","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1128\/AAC.02004-15","volume":"60","author":"A Ayyoub","year":"2016","unstructured":"Ayyoub A, Methaneethorn J, Ramharter M, Djimde AA, Tekete M, Duparc S, et al. Population pharmacokinetics of pyronaridine in pediatric malaria patients. Antimicrob Agents Chemother. 2016;60:1450\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1581_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107196","volume":"64","author":"BE Barber","year":"2024","unstructured":"Barber BE, Webster R, Potter AJ, Llewellyn S, Sahai N, Leelasena I, et al. Characterising the blood-stage antimalarial activity of pyronaridine in healthy volunteers experimentally infected with Plasmodium falciparum. Int J Antimicrob Agents. 2024;64:107196.","journal-title":"Int J Antimicrob Agents"},{"key":"1581_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/bip.23398","volume":"112","author":"C Bailly","year":"2021","unstructured":"Bailly C. Pyronaridine: an update of its pharmacological activities and mechanisms of action. Biopolymers. 2021;112:e23398.","journal-title":"Biopolymers"},{"key":"1581_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12936-018-2509-9","volume":"17","author":"NJ White","year":"2018","unstructured":"White NJ. Anaemia and malaria. Malar J. 2018;17:371.","journal-title":"Malar J"},{"key":"1581_CR12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/1475-2875-8-304","volume":"8","author":"B Tan","year":"2009","unstructured":"Tan B, Naik H, Jang I-J, Yu K-S, Kirsch LE, Shin C-S, et al. Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects. Malar J. 2009;8:304.","journal-title":"Malar J"},{"key":"1581_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jpba.2007.06.018","volume":"45","author":"H Naik","year":"2007","unstructured":"Naik H, Imming P, Schmidt MS, Murry DJ, Fleckenstein L. Development and validation of a liquid chromatography-mass spectrometry assay for the determination of pyronaridine in human blood for application to clinical pharmacokinetic studies. J Pharm Biomed Anal. 2007;45:112\u20139.","journal-title":"J Pharm Biomed Anal"},{"key":"1581_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-065295","volume":"13","author":"M Djimde","year":"2023","unstructured":"Djimde M, Tshiongo JK, Muhindo HM, Tinto H, Sevene E, Traore M, et al. Efficacy and safety of pyronaridine-artesunate (PYRAMAX) for the treatment of P. falciparum uncomplicated malaria in African pregnant women (PYRAPREG): study protocol for a phase 3, non-inferiority, randomised open-label clinical trial. BMJ Open. 2023;13:e065295.","journal-title":"BMJ Open"},{"key":"1581_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116154","volume":"245","author":"WM Schouten","year":"2024","unstructured":"Schouten WM, Roseboom IC, Lucas L, Kabalu Tshiongo J, Muhindo Mavoko H, Kayentao K, et al. Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of the antimalarial drug pyronaridine in human whole blood. J Pharm Biomed Anal. 2024;245:116154.","journal-title":"J Pharm Biomed Anal"},{"key":"1581_CR16","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/psp4.12473","volume":"8","author":"J Lippert","year":"2019","unstructured":"Lippert J, Burghaus R, Edginton A, Frechen S, Karlsson M, Kovar A, et al. Open systems pharmacology community-an open access, open source, open science approach to modeling and simulation in pharmaceutical sciences. CPT Pharmacomet Syst Pharmacol. 2019;8:878\u201382.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1581_CR17","doi-asserted-by":"publisher","first-page":"D1002","DOI":"10.1093\/nar\/gkq1040","volume":"39","author":"H Parkinson","year":"2011","unstructured":"Parkinson H, Sarkans U, Kolesnikov N, Abeygunawardena N, Burdett T, Dylag M, et al. ArrayExpress update\u2014an archive of microarray and high-throughput sequencing-based functional genomics experiments. Nucleic Acids Res. 2011;39:D1002-1004.","journal-title":"Nucleic Acids Res"},{"key":"1581_CR18","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s11095-006-9210-3","volume":"24","author":"T Rodgers","year":"2007","unstructured":"Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res. 2007;24:918\u201333.","journal-title":"Pharm Res"},{"key":"1581_CR19","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/jps.20322","volume":"94","author":"T Rodgers","year":"2005","unstructured":"Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94:1259\u201376.","journal-title":"J Pharm Sci"},{"key":"1581_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.tiv.2007.09.010","volume":"22","author":"W Schmitt","year":"2008","unstructured":"Schmitt W. General approach for the calculation of tissue to plasma partition coefficients. Toxicol In Vitro. 2008;22:457\u201367.","journal-title":"Toxicol In Vitro"},{"key":"1581_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/oxfordjournals.rpd.a006305","volume":"105","author":"BB Boecker","year":"2003","unstructured":"Boecker BB. Reference values for basic human anatomical and physiological characteristics for use in radiation protection. Radiat Prot Dosimetry. 2003;105:571\u20134.","journal-title":"Radiat Prot Dosimetry"},{"key":"1581_CR22","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2012.026","volume":"4","author":"A Bartoloni","year":"2012","unstructured":"Bartoloni A, Zammarchi L. Clinical aspects of uncomplicated and severe malaria. Mediterr J Hematol Infect Dis. 2012;4:e2012026.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"1581_CR23","unstructured":"ESQlabs GmbH. ESQlabs\u2019 training platform \u201clysosomal trapping\u201d [Internet]. [cited 2025 May 11]. Available from: https:\/\/learn.esqlabs.com\/."},{"key":"1581_CR24","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a035311","volume":"12","author":"E Lloyd-Evans","year":"2020","unstructured":"Lloyd-Evans E, Waller-Evans H. Lysosomal Ca2+ homeostasis and signaling in health and disease. Cold Spring Harb Perspect Biol. 2020;12:a035311.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1581_CR25","unstructured":"Saftig P. Physiology of the lysosome. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS [Internet]. Oxford: Oxford PharmaGenesis; 2006 [cited 2025 Jul 24]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK11604\/."},{"key":"1581_CR26","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ejps.2017.08.014","volume":"109","author":"F Assmus","year":"2017","unstructured":"Assmus F, Houston JB, Galetin A. Incorporation of lysosomal sequestration in the mechanistic model for prediction of tissue distribution of basic drugs. Eur J Pharm Sci. 2017;109:419\u201330.","journal-title":"Eur J Pharm Sci"},{"key":"1581_CR27","unstructured":"CDC - DPDx - Diagnostic procedures - blood specimens [Internet]. 2019 [cited 2025 May 11]. Available from: https:\/\/www.cdc.gov\/dpdx\/diagnosticprocedures\/blood\/microexam.html."},{"key":"1581_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12936-017-1731-1","volume":"16","author":"NJ White","year":"2017","unstructured":"White NJ. Malaria parasite clearance. Malar J. 2017;16:88.","journal-title":"Malar J"},{"key":"1581_CR29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1475-2875-11-102","volume":"11","author":"AR Kreeftmeijer-Vegter","year":"2012","unstructured":"Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, Bierman WFW, Clerinx J, van Veldhuizen CKW, et al. Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium. Malar J. 2012;11:102.","journal-title":"Malar J"},{"key":"1581_CR30","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/j.1462-5822.2006.00847.x","volume":"9","author":"Y Kuhn","year":"2007","unstructured":"Kuhn Y, Rohrbach P, Lanzer M. Quantitative pH measurements in Plasmodium falciparum-infected erythrocytes using pHluorin. Cell Microbiol. 2007;9:1004\u201313.","journal-title":"Cell Microbiol"},{"key":"1581_CR31","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1124\/dmd.115.065920","volume":"43","author":"JE Sager","year":"2015","unstructured":"Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification. Drug Metab Dispos. 2015;43:1823\u201337.","journal-title":"Drug Metab Dispos"},{"key":"1581_CR32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1128\/AAC.03829-14","volume":"59","author":"P Jittamala","year":"2015","unstructured":"Jittamala P, Pukrittayakamee S, Ashley EA, Nosten F, Hanboonkunupakarn B, Lee SJ, et al. Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. Antimicrob Agents Chemother. 2015;59:505\u201313.","journal-title":"Antimicrob Agents Chemother"},{"key":"1581_CR33","unstructured":"Pyramax - opinion on medicine for use outside EU [Internet]. [cited 2025 Aug 14]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/outside-eu-assessment-variation\/pyramax-h-w-2319-x-0008-g-assessment-report-extension_en.pdf."},{"key":"1581_CR34","unstructured":"Shin Poong Pharmaceuticals Co. Ltd. Application for Inclusion in WHO Model List of Essential Medicine - pyronaridine tetraphosphate\/artesunate. 2016 Nov."},{"key":"1581_CR35","unstructured":"Computer vision assisted data extraction from charts using WebPlotDigitizer [Internet]. [cited 2025 Aug 14]. Available from: https:\/\/automeris.io\/."},{"key":"1581_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12936-015-0586-6","volume":"14","author":"A Pascual","year":"2015","unstructured":"Pascual A, Madamet M, Briolant S, Gaillard T, Amalvict R, Benoit N, et al. Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine. Malar J. 2015;14:49.","journal-title":"Malar J"},{"key":"1581_CR37","unstructured":"World Health Organization (WHO). Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity [Internet]. [cited 2025 May 11]. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-NMH-NHD-MNM-11.1."},{"key":"1581_CR38","unstructured":"Simulations Plus. PKanalix\u00ae [Internet]. [cited 2025 May 11]. Available from: https:\/\/www.simulations-plus.com\/software\/monolix\/pkanalix\/."},{"key":"1581_CR39","unstructured":"Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1968;405:5\u201337."},{"key":"1581_CR40","first-page":"1","volume":"19","author":"OA Adegoke","year":"2006","unstructured":"Adegoke OA, Babalola CP, Oshitade OS, Famuyiwa AA. Determination of the physicochemical properties of pyronaridine\u2013a new antimalarial drug. Pak J Pharm Sci. 2006;19:1\u20136.","journal-title":"Pak J Pharm Sci"},{"key":"1581_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007890","volume":"13","author":"TR Lane","year":"2019","unstructured":"Lane TR, Massey C, Comer JE, Anantpadma M, Freundlich JS, Davey RA, et al. Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection. PLoS Negl Trop Dis. 2019;13:e0007890.","journal-title":"PLoS Negl Trop Dis"},{"key":"1581_CR42","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1124\/jpet.120.000385","volume":"376","author":"X Liu","year":"2021","unstructured":"Liu X, Jusko WJ. Physiologically based pharmacokinetics of lysosomotropic chloroquine in rat and human. J Pharmacol Exp Ther. 2021;376:261\u201372.","journal-title":"J Pharmacol Exp Ther"},{"key":"1581_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106044","volume":"56","author":"J Homolak","year":"2020","unstructured":"Homolak J, Kodvanj I. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. Int J Antimicrob Agents. 2020;56:106044.","journal-title":"Int J Antimicrob Agents"},{"key":"1581_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-021-03593-6","volume":"20","author":"YD Compaor\u00e9","year":"2021","unstructured":"Compaor\u00e9 YD, Zongo I, Som\u00e9 AF, Barry N, Niki\u00e9ma F, Kabor\u00e9 TN, et al. Hepatic safety of repeated treatment with pyronaridine-artesunate versus artemether-lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso. Malar J. 2021;20:64.","journal-title":"Malar J"},{"key":"1581_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","volume":"70","author":"E St\u00f8rset","year":"2014","unstructured":"St\u00f8rset E, Holford N, Midtvedt K, Bremer S, Bergan S, \u00c5sberg A. Importance of hematocrit for a tacrolimus target concentration strategy. Eur J Clin Pharmacol. 2014;70:65\u201377.","journal-title":"Eur J Clin Pharmacol"},{"key":"1581_CR46","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/1475-2875-11-270","volume":"11","author":"SL Croft","year":"2012","unstructured":"Croft SL, Duparc S, Arbe-Barnes SJ, Craft JC, Shin C-S, Fleckenstein L, et al. Review of pyronaridine anti-malarial properties and product characteristics. Malaria J. 2012;11:270.","journal-title":"Malaria J"},{"key":"1581_CR47","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4269\/ajtmh.17-0889","volume":"99","author":"MD Lim","year":"2018","unstructured":"Lim MD. Dried blood spots for global health diagnostics and surveillance: opportunities and challenges. Am J Trop Med Hyg. 2018;99:256\u201365.","journal-title":"Am J Trop Med Hyg"},{"key":"1581_CR48","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/590707","volume":"2010","author":"SH Park","year":"2010","unstructured":"Park SH, Pradeep K. Absorption, distribution, excretion, and pharmacokinetics of 14C-pyronaridine tetraphosphate in male and female Sprague-Dawley rats. J Biomed Biotechnol. 2010;2010:590707.","journal-title":"J Biomed Biotechnol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01581-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01581-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01581-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:32:44Z","timestamp":1766053964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01581-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1581"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01581-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was produced by the PYRAPREG study which is part of the EDCTP2 program (grant number RIA2017MC-2025-PYRAPREG) and the Global Health EDCTP3 Joint Undertaking (Grant agreement ID: 101145638 PYRAPREG-extended), both programs supported by the European Union. The views and opinions of authors expressed herein do not necessarily state or reflect those of EDCTP. T.D. was supported by the Swedish Research Council (VR 2022-01251).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J.S. is an employee of Shin Poong Pharm. Co. Ltd, which provided the study drug. Alwin Huitema is an Editorial Board member of Clinical Pharmacokinetics. Alwin Huitema was not involved in the\nselection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. All other authors declare that they have no competing interests relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The raw data are available upon reasonable request by an email to the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The model files are provided as supplementary material.\u00a0Other codes are available upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The authors affirm that human research participants provided informed consent for publication of their data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"U.D.A., K.K., T.D., H.M.M., J.K.T., D.Y., F.A.K., V.M., E.S., A.V., and J.S. contributed to protocol development, study conduct, study registration, recruitment, and data collection. W.S. performed the bioanalysis and measured the study samples. W.C., A.H., and T.D. conducted the PBPK modelling. The manuscript was drafted and reviewed by W.C., A.H., and T.D. All authors reviewed, commented on, and approved the final submitted version of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"The PYRAPREG trial (PACTR202011812241529) was conducted in accordance with the principles of the Declaration of Helsinki. Ethical approval was obtained from the following committees: the Ethics Committee for Health Research in Burkina Faso, the National Health Ethics Committee in the Democratic Republic of Congo, the Ethics Committee of the Faculty of Medicine and Odontostomatology\/Faculty of Pharmacy in Mali, the Gambia Government\/MRCG Joint Ethics Committee, and the National Bioethics Committee for Health in Mozambique. Written informed consent was obtained from all participants prior to their inclusion in the study. A four-part phase I clinical trial (Protocol number SP-C-001-03) was conducted at the Clinical Trial Center of Seoul National University, Seoul, South Korea, in accordance with Good Clinical Practice (GCP) guidelines and the Declaration of Helsinki. Ethical approval was granted by the Institutional Review Board of Seoul National University. Written informed consent was obtained from each participant prior to study participation.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval\/Consent to Participate"}}]}}